Advanced
Product
Solutions
Partners
Resources
Company
Toggle menu
Home
/
Alar Pharmaceuticals
Alar Pharmaceuticals
Overview
Locations
Financials
Operating Metrics
Human Capital
Key People
Competitors
Supplier Risk
Alar Pharmaceuticals
Stock Price
NT$169
2024-10-29
Market Capitalization
NT$11.1 B
2024-10-29
Revenue
NT$2.8 M
FY, 2025
Alar Pharmaceuticals Summary
Company Summary
Overview
Alar Pharmaceuticals is a new drug development company. It offers opioid use disorder, chronic pain, major depressive disorder, and other services.
Type
Public
Status
Active
Founded
2016
Website
http://alarpharm.com
Cybersecurity rating
Sectors
Healthcare
drug development
medical diagnostics
Homepage
Linkedin
Table of Contents
Financials
Competitors
Alar Pharmaceuticals Financials
Summary Financials
Revenue (FY, 2025)
NT$2.8M
Gross profit (FY, 2025)
NT$2.8M
Net income (FY, 2025)
(NT$79.7M)
Cash (FY, 2025)
NT$1.8B
EBIT (FY, 2025)
(NT$167.9M)
Enterprise value
$9.3B
Competitors and Similar Companies
Curyx Partners Therapeutics
Healthcare - Private
Precision Diagnostics
Healthcare - Private
M3
Healthcare - Public
APTEEUS
Healthcare - Private
Compare competitors
Footer menu
Contact us
Product
Intelligence Suite
Supplier Intelligence Platform
Craft Intelligence Portal
Craft API
Craft for Teams
Supplier Intelligence Platform
Craft Alerts
Craft N-Tier Mapping
Craft Risk Hub
Chrome extension
Solutions
Supplier Intelligence
Sales Intelligence
Aerospace and Defense
Resources
Resource center
Blog
Company
About
Careers
Contact
Terms of Service
Privacy Policy
Security
© Craft.co 2026
Share price data provided by IEX
Back
to top